News Sentiment

LUNG sentiment intelligence

Pulmonx Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 1.54 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

77/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+10.8% over one week, +12.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 77/100 classification
One-week reaction 10.8% Price confirming higher
Trend fit Trend inactive 12.4% over four weeks
Fair value -74.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 43
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 12
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 10
TradingKey 7
TradingView 6
MarketBeat 3
StockStory 2
GlobeNewswire 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Earnings 30
Market update 24
Capital return 1
Balance sheet 1
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Kalkine Media Direct company coverage

Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz

Pulmonx (NASDAQ:LUNG) is attracting attention as a penny stock due to its focus on severe emphysema treatment. The company's key products, the Zephyr Endobronchial Valve and the Chartis system, are highlighted for their role in improving lung function in affected patients. This r

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 20:45
Source
Kalkine Media
AD HOC NEWS Direct company coverage

Pulmonx Corp highlights lung device strategy as a specialized medtech player

Pulmonx Corp positions itself as a specialized medical technology company focusing on minimally invasive devices for severe emphysema and chronic respiratory conditions. Its business model centers on bronchoscopic procedures, generating revenue from implantable devices and associ

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 19:32
Source
AD HOC NEWS
TradingView Direct company coverage

Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF

This page from TradingView provides financial information for Pulmonx Corp. under the ticker LSX:A2P1AF. It focuses on the enterprise value to EBITDA forward metric, but the actual data values are not visible in the provided content. The page also includes various navigation and

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 06:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Pulmonx Corp. – LSX:A2P1AF

This article focuses on the "Enterprise value to EBIT forward" metric for Pulmonx Corp. (LSX:A2P1AF). It appears to be a financial data snippet from TradingView, providing an overview of a specific valuation ratio for the company's stock. The content points to financial data avai

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 04:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF

This article provides the "Price to earnings forward" valuation metric for Pulmonx Corp. (LSX:A2P1AF). It indicates the value and change of this financial data point over a period. The information is presented within the context of TradingView's platform, which offers various fin

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 02:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Pulmonx Corp. – DUS:4NI

This article provides the "Price to earnings forward" data for Pulmonx Corp. (DUS:4NI) on the TradingView platform. It details the company's financial information, presented within the context of the Düsseldorf Stock Exchange. The content is primarily a data page on a financial p

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 01:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Pulmonx Corp. – DUS:4NI

This page from TradingView provides financial information for Pulmonx Corp. (4NI) listed on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The article includes standard market data and copyright information, indicating that the market fo

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 01:10
Source
TradingView
Ad-hoc-news.de Direct company coverage

Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospects

Pulmonx Corp (PULM) focuses on developing minimally invasive medical devices for severe emphysema and other chronic obstructive pulmonary diseases, targeting a significant unmet medical need. The company's business model involves selling specialized devices to healthcare provider

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 15:40
Source
Ad-hoc-news.de
TradingView Direct company coverage

Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG)

This article provides financial actuals and estimates for Pulmonx Corporation (NASDAQ: LUNG), including its current stock price, historical performance, analyst forecasts, and company financials. It details the company's market capitalization, last quarter's earnings and revenue,

Tone
Negative 29/100
Event
Earnings
Published
26 Jun 2026 01:11
Source
TradingView
TradingKey Direct company coverage

Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis

Pulmonx Corp (LUNG) has a stable financial status but low operating efficiency, ranking 142 out of 204 in the Healthcare Equipment & Supplies industry with a financial score of 6.69. The company's latest quarterly revenue decreased by 8.66% year-over-year to $20.59 million, and i

Tone
Negative 40/100
Event
Earnings
Published
23 Jun 2026 23:40
Source
TradingKey
TradingKey Direct company coverage

Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pulmonx Corp (LUNG), highlighting its price momentum score of 5.32 within the Healthcare Equipment & Supplies industry. It details the stock's current trading range between a resistance level of $1.59 and a support level of $1.09, sug

Tone
Negative 32/100
Event
Market update
Published
18 Jun 2026 22:09
Source
TradingKey
TradingKey Direct company coverage

Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Pulmonx Corp (LUNG), highlighting its current earnings forecast score, average price target of $4.50, and analyst ratings. Based on 5 analysts, the stock has a "Buy" trend. The article also includes expected revenue and EPS for upcom

Tone
Positive 69/100
Event
Earnings
Published
18 Jun 2026 11:09
Source
TradingKey
TradingKey Direct company coverage

Pulmonx Corp (LUNG) Institutional Confidence

Pulmonx Corp (LUNG) has an institutional shareholding score of 7.00, placing it 79th out of 204 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 10.02% quarter-over-quarter to 87.40%. James Simons is noted as the largest inst

Tone
Positive 68/100
Event
Market update
Published
18 Jun 2026 11:09
Source
TradingKey
TradingKey Direct company coverage

Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Pulmonx Corp (LUNG), noting its current valuation score is 7.71, ranking 137 out of 204 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -0.97, which represents a decrease from its recent high

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Pulmonx Corp (LUNG), detailing its revenue by geographical region for the fiscal year 2023. The United States contributed the largest portion of revenue at 63.01% ($57.02 million), followed by Europe, Middle-East and Africa ("EMEA") a

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:09
Source
TradingKey
TradingKey Direct company coverage

Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pulmonx Corp's (LUNG) dividend and stock split history, noting that no dividend data or stock split data is available. It shows the current stock price, market cap, and links to various company and market analysis sections on the TradingKey pl

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:09
Source
TradingKey
Stock Titan Direct company coverage

[Form 4] Pulmonx Corp Insider Trading Activity

Pulmonx Corp director Thomas William Burns has been granted 40,000 Restricted Stock Units (RSUs) as compensation, not through a market purchase. These RSUs, valued at $0.0000 per share, will vest on the earlier of one year from the June 5, 2026 grant date or the date of the Annua

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 18:39
Source
Stock Titan
Stock Titan Direct company coverage

Pulmonx (LUNG) director receives 40,000-share RSU stock grant

Pulmonx Corp director Dana G. Mead Jr. was granted 40,000 Restricted Stock Units (RSUs) which are payable in common stock. This is an equity compensation award, not an open-market purchase, with a grant price of $0.00 per share. These RSUs will vest on the earlier of June 5, 2026

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 06:40
Source
Stock Titan
Stock Titan Direct company coverage

LUNG SEC Filings - Pulmonx Corp 10-K, 10-Q, 8-K Forms

This page provides access to SEC filings for Pulmonx Corporation (LUNG), a medical technology company. It includes 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. The filings detail the company's financial results, governance, compensa

Tone
Neutral 50/100
Event
Earnings
Published
10 Jun 2026 03:39
Source
Stock Titan
Sahm Direct company coverage

Don't Ignore The Insider Selling In Pulmonx

Pulmonx Corporation's CEO and President, Glendon French, recently sold US$87k worth of stock at US$1.55 per share, following an earlier sale of US$97k below the current price. Insiders own 5.1% of Pulmonx shares, worth approximately US$3.3m, but there have been no insider purchas

Tone
Negative 29/100
Event
Market update
Published
07 Jun 2026 22:11
Source
Sahm
Stock Titan Direct company coverage

Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding

Pulmonx Corp's Chief Science & Technology Officer, Radhakrishnan Srikanth, sold 14,497 shares of common stock on June 1, 2026, across four transactions at $1.54 per share. These sales totaling $22,325 were made exclusively to cover tax withholding obligations stemming from the ve

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 16:09
Source
Stock Titan
Investing.com UK Direct company coverage

Pulmonx general counsel David Lehman sells $22,474 in stock

David Aaron Lehman, General Counsel at Pulmonx Corp, sold 14,594 shares of company stock worth $22,474 on June 1, 2026, to cover tax obligations from vested RSUs. This transaction occurred as Pulmonx faces financial challenges, including quickly burning through cash and remaining

Tone
Negative 29/100
Event
Balance sheet
Published
04 Jun 2026 04:40
Source
Investing.com UK
Stock Titan Direct company coverage

Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations

Pulmonx Corp's Chief Commercial Officer, Geoffrey Beran Rose, sold 8,023 shares of common stock at $1.54 per share on June 1, 2026. These sales were conducted to cover tax withholding obligations associated with the vesting of his Restricted Stock Units from 2023, 2024, 2025, and

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations

Pulmonx Corp General Counsel David Aaron Lehman sold 14,594 shares of common stock at $1.54 per share on June 1, 2026. These sales were executed in four transactions solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 202

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding

Pulmonx Corp CEO Glendon E. French III sold 56,149 shares of common stock on June 1-2, 2026, at prices between $1.54 and $1.57 per share. These sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on March 1, 2023, a

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 20:09
Source
Stock Titan